Expanding role of bisphosphonate therapy in children☆,☆☆
References (37)
- et al.
Diphosphonates in the treatment of myositis ossificans
Lancet
(1969) Bisphosphonate therapy
Am J Med Sci
(1997)- et al.
Use and complications of high-dose disodium etidronate therapy in fibrodysplasia ossificans progressiva
J Pediatr
(1977) - et al.
Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn
J Pediatr
(1999) - et al.
Development of bone mass and bone density of the spine and femoral neck—a prospective study of 65 children and adolescents
Bone Miner
(1993) - et al.
Idiopathic arterial calcification in siblings: radiological diagnosis and successful treatment
J Pediatr
(1978) - et al.
Idiopathic arterial calcification of infancy: prenatal and postnatal effects of therapy in an infant
J Pediatr
(1992) - et al.
Mineralisation defects with pamidronate therapy for Paget’s disease
Lancet
(1993) - et al.
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone
Lancet
(1994) - et al.
Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate
Clin Oncol
(1996)
Pamidronate disodium and possible ocular adverse drug reactions
Am J Ophthalmol
(1994)
Renal failure associated with intravenous diphosphonates
Lancet
(1983)
Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis
Medicine
(1997)
Bisphosphonates
Arch Dis Child
(1997)
Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases
Drugs
(1996)
Bisphosphonates in osteoporosis: an introduction
Osteoporosis Int
(1993)
Etidronic acid: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease
Drugs Aging
(1994)
Bisphosphonates: mechanisms of action
J Clin Invest
(1996)
Cited by (75)
Drug-induced osteopetrosis
2023, BoneAntiresorptive and anti-angiogenic drug therapy in the pediatric population with reference to medication-related osteonecrosis of the jaw
2023, International Journal of Oral and Maxillofacial SurgerySevere neonatal hypercalcemia revealing congenital mesoblastic nephroma: A case report and management of neonatal hypercalcemia: Severe neonatal hypercalcemia revealing congenital mesoblastic nephroma
2022, Archives de PediatrieCitation Excerpt :Bisphosphonates have a delayed (24–48 h) and persistent effect [5,7,9]. They should be used with caution in cases of acute kidney injury and only once the child is well hydrated [9]. Calcitonin inhibits the bone-resorbing activity of osteoclasts and inhibits tubular reabsorption of calcium, promoting renal excretion of calcium [5].
Regulation of Fluids and Electrolytes
2011, Smith's Anesthesia for Infants and Children: Expert Consult Premium Edition - Enhanced Online Features and PrintRegulation of Fluids and Electrolytes
2011, Smith's Anesthesia for Infants and ChildrenSkeletal maturation and bone mineralization in the pediatric rheumatic diseases
2011, Textbook of Pediatric Rheumatology
Copyright © 1999 Mosby, Inc. All rights reserved.